People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eliem Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $253.2M | $1.3B | 2019 |
Simon Tate at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Simon Tate on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Adam Rosenberg | 1 | 6 |
| Stephen Thomas | 1 | 5 |
| Liam Ratcliffe | 1 | 4 |
| Erin Lavelle | 1 | 3 |
| Julio Vega | 1 | 3 |
| Aoife Brennan | 1 | 2 |
| Robert Azelby | 1 | 2 |
| David-Alexandre Gros | 1 | 2 |
| Harald Stock | 1 | 1 |
| Judith Dunn | 1 | 1 |
| Valerie Morisset | 1 | 1 |
| James Bucher | 1 | 1 |
| Leone Patterson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.